WELBIO is an inter-university life sciences research institute based in Wallonia, Belgium. WELBIO is funded by the Walloon Region. Our mission is to support strategic fundamental research through carefully selected projects from universities in the Wallonia-Brussels Federation, with a view to transforming their discoveries into industrial applications in all fields of biotechnology.
For the third time, Pr. Cédric Blanpain – WELBIO investigator at the Université libre de Bruxelles - has obtained a grant from the European Research Council (ERC). This new project called “TrackingTumorStates” aims to define at the single cell resolution, the mechanisms regulating tumor transition states, responsible for tumor growth, differentiation, invasion, metastasis and resistance to therapy.
Lung cancer remains very challenging to treat, at least because of intrinsic or acquired resistance of lung cancer cells to some targeted therapies. Combinatory approches are needed to circumvent both types of resistance and new therapeutic targets are consequently needed. A study by Prof. Alain Chariot (WELBIO investigator at the GIGA, Liège) and his team consisted in defining the RNF113A protein as a new target for the treatment of lung tumours. This study has been published in Nature Communications.
Two WELBIO investigators from Université libre de Bruxelles have obtained Consolidator Grants from the European Research Council (ERC). Their projects are dedicated to the Blood-Brain Barrier and to multidrug-resistant bacteria.